German China

Diagnostic Assays Amsbio Launches New Aptamers for Targeting SARS-CoV-2 Proteins

Editor: MA Alexander Stark

Amsbio has further expanded its product range to help in the fight against Covid-19 with the introduction of a new range of aptamers targeting SARS-CoV-2 proteins to aid development of new kits and assays.

Related Vendors

To better understand the genetic architecture of host proteins interacting with SARS-CoV-2 or mediating host response to COVID-19 - using an aptamer-based technique can help to identify new or repurpose existing drugs targeting those proteins.
To better understand the genetic architecture of host proteins interacting with SARS-CoV-2 or mediating host response to COVID-19 - using an aptamer-based technique can help to identify new or repurpose existing drugs targeting those proteins.
(Source: Amsbio)

Aptamers are small single-stranded RNA or DNA oligonucleotides that fold in a three-dimensional conformation allowing them to bind specifically to a target. This target can be an organic molecule, free or carried in cells or tissues, or inorganic components, such as metal ions. Aptamers have generated significant interest as promising tools, that compete with monoclonal antibodies, for detection and inhibition of specific markers of human diseases because they offer high specificity for their target, no to low immunogenicity and easy in vitro selection.

To better understand the genetic architecture of host proteins interacting with SARS-CoV-2 or mediating host response to Covid-19 — using an aptamer-based technique can help to identify new or repurpose existing drugs targeting those proteins.

As aptamers bind targets with high selectivity and specificity, they are an ideal tool to help develop new approaches to early-stage diagnostic assay and adequate therapy. With Amsbio aptamers targeting SARS-CoV-2 S1 protein, S2 protein, RBD protein or nucleocapsid protein, they can be used in wide range of detection methods and for development of Covid-19 diagnostic assays.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:47739741)